Targeted therapies in gastrointestinal stromal tumors

Seminars in Diagnostic Pathology

Volumn 25, Issue 4, 2008, Pages 295-303

  Antonescu, Cristina R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

GIST; Imatinib; Kinase inhibitors; Sunitinib; Targeted therapy

Indexed keywords

B RAF KINASE; DASATINIB; FLAVOPIRIDOL; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TANESPIMYCIN; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL HETEROGENEITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG INHIBITION; DRUG RESISTANCE; DRUG RESPONSE; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; METASTASIS; MOLECULAR THERAPY; MONOTHERAPY; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME; TRANSCRIPTION REGULATION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 53749090994     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2008.08.004     Document Type: Article

References (54)

1. Ma Y., Cunningham M.E., Wang X., et al. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 274 (1999) 13399-13402
2. Chan P.M., Ilangumaran S., La Rose J., et al. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 23 (2003) 3067-3078
3. Mol C.D., Dougan D.R., Schneider T.R., et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279 (2004) 31655-31663
4. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
5. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
6. Agaram N.P., Wong G.C., Guo T., et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47 (2008) 853-859
7. Besmer P., Murphy J.E., George P.C., et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320 (1986) 415-421
8. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
9. Demetri G, Desai J, Flecther JA, et al: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). ASCO Annual Meeting 2004
10. Kebebew E., Weng J., Bauer J., et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246 (2007) 466-470 discussion 470-471
11. Michaloglou C., Vredeveld L.C., Mooi W.J., et al. BRAF(E600) in benign and malignant human tumours. Oncogene 27 (2008) 877-895
12. Minoo P., Moyer M.P., and Jass J.R. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol 212 (2007) 124-133
13. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
14. DeMatteo R.P., Heinrich M.C., El-Rifai W.M., et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33 (2002) 466-477
15. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
16. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
17. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
18. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
19. Debiec-Rychter M., Dumez H., Judson I., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40 (2004) 689-695
20. Agaram N.P., Laquaglia M.P., Ustun B., et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14 (2008) 3204-3215
21. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 (2006) 1093-1103
22. Lee J.L., Ryu M.H., Chang H.M., et al. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. Jpn J Clin Oncol 36 (2006) 704-711
23. DeMatteo R.P., Maki R.G., Singer S., et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245 (2007) 347-352
24. Gronchi A., Fiore M., Miselli F., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245 (2007) 341-346
25. Andtbacka R.H., Ng C.S., Scaife C.L., et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14 (2007) 14-24
26. Sym S.J., Ryu M.H., Lee J.L., et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol 98 (2008) 27-33
27. Blay J, Berthaud P, Perol D, et al: Continuous vs. intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. ASCO Annual Meeting 2004
28. Abbeele A, Badawi R, Manola J, et al: Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. J Clin Oncol; ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:3012, 2004 (suppl)
29. Barnes G., Bulusu V.R., Hardwick R.H., et al. A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec). Int J Surg 3 (2005) 206-212
30. Therasse P., Le Cesne A., Van Glabbeke M., et al. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer 41 (2005) 1426-1430
31. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 7 (2005) 307-311
32. Van Glabbeke M., Verweij J., Casali P.G., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23 (2005) 5795-5804
33. Scaife C.L., Hunt K.K., Patel S.R., et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 186 (2003) 665-669
34. Agaram N.P., Besmer P., Wong G.C., et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13 (2007) 170-181
35. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
36. Debiec-Rychter M., Cools J., Dumez H., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128 (2005) 270-279
37. Wardelmann E., Merkelbach-Bruse S., Pauls K., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12 (2006) 1743-1749
38. Pauwels P., Debiec-Rychter M., Stul M., et al. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 47 (2005) 41-47
39. Liegl B., Hornick J.L., Antonescu C., et al. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol (2008) (in press)
40. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24 (2006) 4764-4774
41. Fletcher J.A., Corless C.L., Dimitrijevic S., et al. Mechanisms of resistance to imatinib mesylate in advanced gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 22 (2003) 815 (A3275)
42. Mahadevan D., Cooke L., Riley C., et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26 (2007) 3909-3919
43. Zalcberg J.R., Verweij J., Casali P.G., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41 (2005) 1751-1757
44. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
45. Maki R.G., Fletcher C.D., Heinrich M.C., et al. SUI 11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 23 (2005) 9011
46. Guo T., Agaram N.P., Wong G.C., et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 13 (2007) 4874-4881
47. Verstovsek S., Golemovic M., Kantarjian H., et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104 (2005) 1230-1236
48. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
49. Nagar B., Bornmann W.G., Pellicena P., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62 (2002) 4236-4243
50. Fabbro D., Ruetz S., Bodis S., et al. PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15 (2000) 17-28
51. Growney J.D., Clark J.J., Adelsperger J., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106 (2005) 721-724
52. Bauer S., Yu L.K., Demetri G.D., et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66 (2006) 9153-9161
53. Sambol E.B., Ambrosini G., Geha R.C., et al. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 66 (2006) 5858-5866
54. Bauer S., Duensing A., Demetri G.D., et al. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 26 (2007) 7560-7568